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The Yes-associated protein (YAP) is a transcriptional co-activator upregulating genes that promote cell growth and
inhibit apoptosis. The main dysregulation of the Hippo pathway in tumors is due to YAP overexpression, promoting
epithelial to mesenchymal transition, cell transformation, and increased metastatic ability. Moreover, it has recently
been shown that YAP plays a role in sustaining resistance to targeted therapies as well. In our work, we evaluated the
role of YAP in acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in lung cancer.
In EGFR-addicted lung cancer cell lines (HCC4006 and HCC827) rendered resistant to several EGFR inhibitors, we
observed that resistance was associated to YAP activation. Indeed, YAP silencing impaired the maintenance of
resistance, while YAP overexpression decreased the responsiveness to EGFR inhibitors in sensitive parental cells. In
our models, we identified the AXL tyrosine kinase receptor as the main YAP downstream effector responsible for
sustaining YAP-driven resistance: in fact, AXL expression was YAP dependent, and pharmacological or genetic AXL
inhibition restored the sensitivity of resistant cells to the anti-EGFR drugs. Notably, YAP overactivation and AXL
overexpression were identified in a lung cancer patient upon acquisition of resistance to EGFR TKIs, highlighting the
clinical relevance of our in vitro results. The reported data demonstrate that YAP and its downstream target AXL play a
crucial role in resistance to EGFRTKIs and suggest that a combined inhibition of EGFR and the YAP/AXL axis could be a
good therapeutic option in selected NSCLC patients.
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Resistance to targeted therapy is a major issue for cancer treatments.
The lesson learned from the clinic reveals that, despite the presence in
cancer cells of the genetic lesions predictive of drug response and
regardless of an initial response to therapy, at some point, tumors
acquire the ability to overcome targeted drug activity and start
regrowing. This is the so-called “secondary or acquired resistance.”
These events are well recapitulated in vitro, where cancer cells exposed
to a drug for a long period of time become resistant through
mechanisms often identical to those observed in patients [1,2].
Indeed, many efforts have been made to create in vitro models of
resistance to study and possibly bypass tumor resistance and to offer
patients efficient second-line treatments designed on the identified
mechanisms of resistance.In this frame, several researchers have rendered lung cancer cells
addicted to EGFR resistant to EGFR tyrosine kinase inhibitors
(TKIs). Exploiting these in vitro models, different mechanisms
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identified: the most frequent is a second site mutation on the EGFR
itself (the T790M mutation) which reduces the affinity of the EGFR
ATP binding pocket for the drugs, thus allowing EGFR activation in
spite of the presence of EGFR TKIs [3,4]. Other discovered
mechanisms involve MET [5] and HER2 [6] gene amplification,
PIK3CA [7] and BRAF [8] mutations, epithelial to mesenchymal
transition (EMT) [9], NF-KB [10], and AXL activation [11].
Recently, a role for Yes-associated protein (YAP) in mediating
resistance to targeted therapies has been described [12]. The YAP
protein, encoded by the YAP1 gene, is the main mediator of the Hippo
pathway [13]. This pathway, originally identified for its role in
regulating organ size, is involved in many cellular functions which
converge in provoking tumor initiation, progression, andmetastasis and
in reprogramming cancer cells into cancer stem cells [14–16]. In fact,
the YAP pathway is often upregulated in cancer, somehow favoring cell
transformation. The activation of the YAP protein upon external stimuli
(i.e., low cell density) leads to YAP translocation from the cytoplasm to
the nucleus, where it can act, together with TEAD transcription factors,
as transcriptional coactivator of several genes, such as CTGF, CCDN1,
and AXL, thus promoting cell proliferation and survival programs. Vice
versa, when inactive, YAP is phosphorylated and prevalently resides in
the cytoplasm, where it elicits less understood functions [17–19].
In this work, EGFR-addicted lung cancer cell lines were rendered
resistant to several EGFR TKIs to study the possible involvement of
YAP in the acquired resistance to these drugs. Interestingly, many
resistant cells displayed increased activation of the YAP pathway
compared to the parental, non-resistant cell lines. Moving forward and
looking for downstream effector(s) of YAP responsible for resistance
onset and maintenance, we demonstrated the causal involvement of
the AXL tyrosine kinase receptor in YAP-driven resistance to EGFR
TKIs: indeed, AXL was induced in cells with active YAP, and its
pharmacological or genetic inhibition was sufficient to restore the
sensitivity of resistant cells to the anti-EGFR drugs. The described
mechanism is clinically relevant since one of the five examined
patients, who had become resistant to EGFR TKIs through a yet
unknown mechanism, showed YAP overactivation and AXL overex-
pression upon acquisition of resistance. The reported data, sustained
by this case report, open the possibility of translating the anti-AXL
treatment into the clinic.
Material and Methods
Cell Cultures and Compounds
The EGFRmutant non–small cell lung adenocarcinoma (NSCLC)
cell lines HCC4006 (carrying delE746-A750) and HCC827
(carrying delE746-A750 and EGFR amplification) were obtained
from ATCC-Sesto San Giovanni, MI, Italy, and cultured in
RPMI-1640. The HEK293T cells (Human Embryonic Kidney
cells, ATCC) were cultured in ISCOVE. The genetic identity of the
cell lines was periodically controlled by short tandem repeat profiling
(Cell ID, Promega, Madison, WI).
The EGFR mutant NSCLC cell lines were treated with the following
EGFR tyrosine-kinase inhibitors: Erlotinib (Tarceva) and Gefitinib
(Iressa) from Sequoia Research Products (Pangbourne, United Kingdom)
and Afatinib (Gilotrif ) and AZD8931 from Selleckchem (Munich,
Germany).
The YAP constructs were produced as in reference [20]; AXL
targeting shRNAs (#TRCN0000196945 and #TRCN0000195353)were from Sigma Aldrich. GAS6 (#885-GSB) was purchased from
R&D Systems (Abingdon, UK).
To generate resistant cell lines, we used a stepwise dose escalation
method starting from a drug dose near the IC50 of cell viability and then
increasing the dose during a 6-month/1-year period. All the established
resistant sublines were maintained in continuous culture with the
achieved dose that still allowed cell proliferation. All the assays involving
resistant cells were performed in the presence of the TKI to which they
have been rendered resistant at the maximum dose reached at the end of
the dose-escalation exposure period. The only exception is represented
by the Western blot of drug washout, where cells were left untreated.
Quantitative Analysis of mRNAs and gDNA
Total RNAs from cultured cells were extracted using the TRIzol
extraction kit (Thermo Fisher, Waltham, MA) according to the
manufacturer protocol. Quantitative analysis of mRNAs was performed
by reverse transcribing 0.5 μg of total RNA (High Capacity cDNA
ReverseTranscriptionKit, ThermoFisher).GenomicDNAwas extracted
using Wizard SV Genomic DNA purification System (Promega). One
microliter of cDNA or 50 ng of gDNA was amplified and analyzed using
TaqMan Gene Expression Master Mix (Thermo Fisher). ACTB
(actin-Hs01060665_g1) and GREB1 (Hs01738470_cn) were used as
housekeeping gene for cDNA and gDNA, respectively. qRT-PCR was
carried out using ABI PRISM 7900HT. Fold changes were determined
by using ΔΔCT method. Taqman probes were as follows: CTGF
(Hs01026927_g1), AXL (Hs01064444_m1and Hs1443849_cn),
GAS6 (Hs0109035_m1), andMET (hs01277655_cn) (ThermoFisher).
Vimentin and E-cadherin expression was evaluated in SYBER Green.
Primers are available from the authors.
Sanger Sequencing
Mutational analysis of EGFR exon 6 was performed via PCR
amplification of 2 μl of cDNA using AmpliTaq Gold kit (Promega). The
following primers were used: forward: CTCCTCTTGCTGCT
GGTGGT; reverse: ATCTTGACATGCTGCGGTGT. PCR products
were purified using AMPure (Agencourt Bioscience Corp., Beckman
Coulter S.p.A, Milan, Italy) according to manufacturer procedures and
analyzed on a 3730 DNA Analyzer, ABI capillary electrophoresis system
(Thermo Fisher).
Protein Extraction and Western Blot
For Western blot analysis, cells were lysed in LB buffer [2% SDS,
0.5 mol/L Tris-HCl (pH 6.8)]. For stimulation experiments, cells were
starved overnight and treated with GAS6 (100 ng/ml) for 10 minutes in
the presence of EGFR TKI in resistant cells. Western blots were
performed according to standard methods. Primary antibodies were as
follows: anti-YAP #4912, anti-phospo YAP#4911, anti-AXL#8661,
anti–phospho AXL#5724, anti-AKT#9272, anti–phospho AKT#4060,
anti-MAPK#9102, and anti–phospho MAPK#9101, all from Cell
Signaling (Leiden, the Netherlands); anti–β-actin #A3854, anti-vinculin
#V9131, and anti–β-tubulin #T8328 from Sigma; and anti-TBP#ab818
from Abcam (Cambridge, UK). Peroxidase-labeled antirabbit or
antimouse antibodies from Amersham Pharmacia (Milan, Italy) were
used as secondary antibodies, and final signal detection was done with
enhanced chemiluminescence system (Amersham Pharmacia).
Preparation of Cytosolic and Nuclear Protein Extracts
HCC4006 cells were lysed in 500 μl of Buffer A 10× (100 mM
Hepes, 100 mM KCl, 100 mM EDTA, water) supplemented with
Table 1. Characterization of Cells Resistant to EGFR TKIs
Cell Lines Mechanisms of Resistance IC50 Resistant Cells IC50 WT Cells
HCC4006 R400 ERL EMT phenotype 3000 nM 40 nM
R40 GEF EMT phenotype 3000 nM 5 nM
R6 AFA EMT phenotype 160 nM 0.3 nM
R15 AZD EMT phenotype 320 nM 2 nM
HCC827 R100 ERL MET amplification 2500 nM 7.5 nM
R100 GEF MET amplification 2500 nM 7.5 nM
R5 AFA MET amplification N320 nM 0.3 nM
R5 AZD Unknown mechanism 200 nM 0.3 nM
PC9 R100 ERL EGFR T790M mutation 2500 nM 20 nM
R100 GEF EGFR T790M mutation 2500 nM 20 nM
R10 AFA EGFR T790M mutation 40 nM 0.2 nM
R10 AZD EGFR T790M mutation N320 nM 0.5 nM
The mechanism of resistance was evaluated as follows. In HCC4006 cells, we observed increased
expression of vimentin and decreased levels of E-cadherin by qRT-PCR; in HCC827 cells, we
observed MET amplification by qRT PCR on gDNA; in PC9 cells, we found the appearance of the
EGFR T790M mutation by Sanger sequencing (Supplementary Table 1).
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ice. Cells were scraped into a fresh tube, and cell lysates were centrifuged
at 13,500 rpm for 15 minutes at 4°C. Supernatants containing the
cytosolic fraction were collected and transferred into a separate tube.
The pellet containing the nuclei were washed three times with Buffer A
and then lysed with 50 μl of Buffer B (20 mM Hepes, 0.4 M NaCl,
1 mM EDTA, 10% glycerol, water) supplemented with protease
inhibitors and DTT 1 mM. Tubes containing the nuclei were gently
rocked at 4°C for 1 hour and then were centrifuged at 13,500 rpm for
5 minutes. Both the fractions were quantified for the total protein
quantity with BCA Protein Assay Kit (Pierce).
Cell Transfection and Transduction
HCC4006 and HCC827 were transfected with siRNAs using
Lipofectamine 2000 (Thermo Fisher). Transfection reagents plus siRNAs
at final concentration of 20 nMwere distributed in each well of a 96-well
plate incubated in OptiMEM serum-free media for 20minutes, and after
that, 70 μl of cells (2000 cells/70 μl) in media without antibiotics was
added to each well. After 72 hours of growth, cell viability was measured
by using the Cell Titer-Glo Luminescent Cell Viability Assay (Promega).
SiRNA (Sigma Aldrich) sequences are available from the authors.
Lentiviruses were produced as described in [21]. Cells were
transduced with 40 ng/ml of p24.
Cell Viability Assay
For growth curve and cell viability assays, cells were seeded in
quadruplicates in 96-well culture plates (2000 cells/well) in the presence
of the indicated drugs. After 72 hours of growth, cell viability was
measured by using the Cell Titer-Glo Luminescent Cell Viability Assay
(Promega).
Immunohistochemistry on Lung Adenocarcinoma Tissue Specimens
Matched biopsies (either bronchial or tru-cut) from nine patients
affected by advanced lung adenocarcinomas harboringEGFRmutations
and treated with EGFR TKIs, obtained before and after the onset of
resistance, were analyzed by means of immunohistochemistry. A
control group of 10 lung adenocarcinoma cases with matched tissue
samples before and after chemotherapy and lacking EGFR mutations
was also analyzed. Antibodies against pYAP (#4911 Cell Signaling,
diluted 1:50), AXL (Cell Signaling, clone C89E7, diluted 1:50), and
CTGF (Santa Cruz, goat polyclonal, diluted 1:100) were employed
using an automated platform (Ventana Benchmark). The immunohis-
tochemistry signal was assessed using the H-score which is based on the
intensity of the signal and on the percentage of cells stained, and results
in a score ranging from 0 to 300.
The immunohistochemical study was conducted according to
guidelines and regulations by the Research Ethics Committee of the
AOUSan Luigi/University of Turin, as explicated by formal approval to
M. V. of current projects regulating the use of retrospective solid tumor
tissues (see Ethics Committee Approvals no. 167/2015, prot. 17975,
14/11/2015 and no. 204/2016, prot. 20840, 22/12/2016). Before
the analysis, the samples have been anonymized by staff members of the
Department of Oncology at San Luigi Hospital not involved in
the project. No references to the patients can be inferred from the
immunohistochemical characterization presented in the work.
Statistics
Results show one representative experiment out of at least three
different independent experiments. Comparisons were made using
two-tailed Student's t test.Results
The YAP Pathway is Activated in EGFR TKI–Resistant Cells
Since YAP activity has been involved in resistance to B-RAF and
MEK targeted therapies [22], we wondered whether it could also be
implicated in resistance to EGFR targeted therapies in lung cancer
cells. To address this issue, we focused on a panel of lung cancer
cell lines (HCC4006, HCC827, and PC9) addicted to EGFR
(i.e., dependent on EGFR activity for their growth and survival) that
we rendered resistant to four different EGFR TKIs: erlotinib
and gefitinib (first-generation TKIs), afatinib and AZD8931
(second-generation TKIs). Cells were treated for several months
with increasing concentrations of the different drugs until reaching a
dose that was at least five-fold higher than the IC50 (Table 1) and
continuously kept in culture with EGFR inhibitors. All the
experiments on resistant sublines were performed in the presence of
EGFR TKIs if not differently specified. Resistant cells were
characterized for the presence of already known mechanisms of
resistance and for the activation status of EGFR, MET, AKT, and
MAPK (for details, see Supplementary Table 1).
To assess the activity of the Hippo pathway in the resistant cell lines,
we screened them for the expression of connective tissue growth factor
(CTGF) which is considered one of the major transcriptional targets of
YAP [23]. As shown in Figure 1A and Supplementary Figure 1A, in
many resistant cell lines, CTGF expression was significantly higher
compared to the parental cells. Interestingly, CTGF increase could be
observed also in models of acquired resistance to other TKIs
(Supplementary Figure 1B), opening the possibility that YAP activation
is a sharedmechanism of resistance. Since the greatest increase inCTGF
expression was seen in HCC4006 cells resistant to the different EGFR
TKIs and in HCC827 cells resistant to afatinib, we selected these cell
lines for further studies.
According to the literature, upon activation, YAP loses its
phosphorylation in serine 127 and translocates into the nucleus, where
it activates its transcriptional targets (among them, the already
mentioned CTGF) [18]. For this reason, we looked at YAP
phosphorylation status and localization to further prove its activation
in resistant cells. As shown in Figure 1 B and C, YAP was less
phosphorylated in S127 and showed an increased nuclear localization in
resistant cells compared to parental ones, thus indicating a fostering of
YAP pathway activation in resistant cells. Moreover, in resistant cells,
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is not an epiphenomenon due to drug exposure but is a stable
event, possibly having a functional role in maintaining resistance
(Supplementary Figure 2A).
YAP Functionally Controls Cell Response to EGFR TKIs
To understand if YAP activation has a functional role in resistance
maintenance, we genetically inhibited YAP expression in parental and
resistant cells (grown in presence of anti-EGFR drugs) using two
different siRNA sequences. As shown in Figure 2A, YAP silencing
significantly reduced cell viability in resistant cells, while it was
ineffective in parental cells.
In the mirror experiment, the overexpression in HCC4006 parental
cells of either the WT YAP or an active form of YAP carrying a double
mutation in serines 127 and 381 (which renders it unphosphorylable
and thus preferentially located in the nucleus; YAP SS) conferred
resistance to EGFR TKIs (Figure 2B and Supplementary Figure 2B).
Similar results have been obtained in HCC827 cells as well
(Supplementary Figure 2, C and D).Figure 1. YAP is activated in HCC4006 resistant cells. (A) The expression
in HCC4006 resistant cells. Results are expressed as fold change comp
higher in the resistant cell lines compared to their wt counterpart, t
***P b .001. The error bars represent the SD. (B)Western Blot analysis
to the different EGFR TKIs showed decreased YAP S127 phospho
the cytoplasm) compared to parental HCC4006; the amount of
(C) Nucleus-cytoplasm fractionation: cytoplasmsandnuclei ofwt and re
the indicated antibodies. As shown, the amount of nuclear YAP was in
and b-tubulin were used as loading controls of the nuclear and cytopla
afatinib; AZD = AZD8931. R400, R40, R6, R15 = concentrations (nM)Altogether, these results show that YAP activation functionally
regulates cell sensitivity to EGFR TKIs.
YAP Activation Impairs Drug Response Through Induction of
AXL Transcription
Since YAP is able to transcriptionally activate many targets [24], we
wondered which of them is critical in sustaining resistance to EGFR
TKIs. Among the described YAP targets, we focused our attention on
the AXL tyrosine kinase receptor that could, in principle, vicariate the
loss of EGFR signal due to TKI treatment [25]. For this reason, we
evaluated AXL expression in our resistant and parental cells. As
shown, in resistant cells, we observed an increase of AXL expression
both at the RNA (Figure 3A and Supplementary Figure 3A) and at
the protein level (Figure 3B and Supplementary Figure 3B). Notably,
no amplification of the AXL gene was observed at the genomic level
(Supplementary Figure 3C), suggesting that AXL increase might be
due to transcriptional activation. As not only AXL protein amount
but also its phosphorylation was strongly increased in resistant cells,
we evaluated the expression of its ligand, GAS6. GAS6 expression waslevel of CTGF (one of themajor YAP targets) was evaluated by qPCR
ared to wild-type (wt) cells, considered as 1. CTGFmRNA levels were
estifying to an increased YAP activity in resistant cells. **P b .01;
of total cell lysates demonstrates that all the HCC4006 cells resistant
rylation (that inhibits YAP activity by sequestering the protein in
total YAP was unaffected. Actin was used as loading control.
sistant cellswere separately lysed, subjected toWB, andprobedwith
creased in resistant compared to wt cells. TBP (Tata binding protein)
smic fraction, respectively. ERL = erlotinib; GEF = gefitinib; AFA =
of the different drugs to which the cells are resistant.
Figure 2. YAP modulation impinges on resistance to EGFR TKIs.
(A) Viability assay of wt and resistant cells (in presence of EGFR TKIs)
upon YAP silencing with two different siRNA sequences. As shown,
viability of resistant cells was significantly affected by YAP silencing.
(B) HCC4006 wt cells were transduced with the empty vector
(pRRL2), YAP wt, or YAP SS (the constitutively active form of YAP).
Cellswere then treatedwith the indicateddrugs, and cell viabilitywas
assessed 72 hours later. As shown, the overexpression of both YAP
wt and SS protected cells from EGFR TKI treatment. The error bars
represent the SD. **P b .01; ***P b .001. Drug abbreviations as in
Figure 1.
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(Supplementary Figure 3D). However, GAS6 expression was not
directly controlled by YAP as no modulation of GAS6 expression was
observed upon YAP overexpression/inhibition (data not shown).
To prove that increased AXL expression was a consequence of YAP
activation, we genetically interfered with YAP expression. A clear
reduction of AXL expression was observed upon YAP silencing, both in
HCC4006 (Figure 3C) and in HCC827 (Supplementary Figure 3E)
cells. To further strengthen the finding that AXL expression is influenced
by YAP activation, we overexpressed either YAP WT or YAP SS in
parental HCC4006 and HCC827 cells; as shown in Figure 3D and
Supplementary Figure 3F, in both cells, AXL expression was increased.
AXL Genetic or Pharmacological Blockage Revert EGFR TKI
Resistance
The final goal of understanding resistance mechanisms to TKIs is
to find a way to overcome resistance, thus offering an effective
treatment to patients. With this in mind, we wondered whether AXL
could be an actionable target in our system. To address this point, we
first undertook a pharmacological approach. HCC4006 resistant cells(maintained in the presence of the EGFR TKI to which they are
resistant) were co-treated with increasing doses of TP-0903 (a
selective AXL TKI) (Figure 4A) or foretinib (a multikinase inhibitor
active against many tyrosine kinase receptors, including AXL)
(Supplementary Figure 4A). As shown in the graphs, both inhibitors
significantly decreased cell viability in a dose-dependent manner, the
specific TP-0903 inhibitor being more potent than foretinib. As
expected, both TP-0903 (Figure 4B) and foretinib (Supplementary
Figure 4B) induced a strong decrease in AXL phosphorylation and in
the activation of the downstream transducers MAPK and AKT.
Similar results have been obtained in HCC827 resistant cells as well
(Supplementary Figure 4C). Moreover, AXL basal phosphorylation in
HCC4006 resistant cells was further increased by GAS6 stimulation
and reverted by foretinib treatment (Supplementary Figure 4B).
Finally, to validate the pharmacological data, we carried out a
genetic approach, specifically silencing AXL expression with two
different shRNA sequences in HCC4006 resistant cells maintained in
the presence of EGFR TKIs (Supplementary Figure 5). As shown in
Figure 4C, upon AXL silencing, HCC4006 reacquired sensitivity to
EGFR TKIs at a level near that of wt cells (Supplementary Figure 6).
These data highlight the active role of AXL in mediating resistance to
EGFRTKIs in our cellularmodels and open the possibility of considering
AXL an actionable and effective target in EGFR TKI–resistant cells.
Activation of the YAP-AXL Pathway upon Resistance Onset in
Human Lung Adenocarcinomas
To validate our in vitro data, we analyzed tumor slices obtained
from lung cancer patients treated with EGFR TKIs who had become
resistant to the treatment (Supplementary Table 2) as compared to a
control group of lung cancer patients whose tumors were lacking
EGFR mutations and were thus treated with chemotherapy only
(Supplementary Table 3). None of the investigated markers was
significantly correlated with each other, or different in EGFRmutated
versus wt adenocarcinoma samples, or in first biopsies versus samples
at tumor progression, as a whole group (data not shown). With regard
to the nine patients harboring EGFR mutations and treated with
EGFR TKIs, three of them developed the T790M resistance
mutation at the time of progression, whereas in the other six patients,
the mechanism of resistance was unknown (Supplementary Table 2).
Interestingly, in the biopsy of patient #5 obtained upon resistance
onset (tissue sample II), we observed, compared to the biopsy at
diagnosis (tissue sample I), an important activation of the YAP
pathway; indeed, we found decreased pYAP, which is the inactive
form of YAP (from H-score 130 in the first biopsy to 30 in the biopsy
at tumor progression), and increased CTGF expression (from H-score
30 in the first biopsy to 90 in the biopsy at tumor progression).
Concomitantly, AXL expression was significantly increased (AXL
score low: 10 in the biopsy at diagnosis, high: 90 in the biopsy at
relapse) (Figure 5). The relapsed tumor of this patient was negative for
the presence of other known mechanisms of resistance such as ALK
and ROS1 translocations; MET amplification; and BRAF, PI3K,
HER2, and KRAS mutations (data not shown). In summary, three
out of seven investigated patients developed resistance due to the
appearance of the T790M mutation; no other known molecular
alteration was identified in the other analyzed resistant cases.
YAP-associated AXL activation was found in one out of the six
patients not displaying EGFR resistance mutations. This report,
although too small to drive conclusions on the real prevalence of
AXL-driven resistance, strengthens our in vitro data, opening the
Figure 3. YAP induces AXL expression. (A) The expression level of AXL was evaluated by qPCR in HCC4006 resistant cells and compared
to wt cells. Results are expressed as fold change compared to wt cells, considered as 1. AXLmRNA levels were higher in the resistant cell
lines compared to the wild-type counterpart. ***P b .001. The error bars represent the SD. (B) The expression level of AXL in resistant and
parental HCC4006 cells was evaluated byWB. As shown, both AXL expression and activation (phosphorylated AXL, pAXL) were increased
in resistant cells. Actin was used as loading control. (C) AXL expression was evaluated by WB upon YAP silencing in HCC4006 cells. As
shown, AXL expression was reduced upon YAP silencing. Vinculin was used as loading control. (D) HCC4006 cells were transduced with
wt (YAP wt) or active YAP (YAP SS), and the expression of AXL was assessed by WB. As shown, AXL expression was induced upon YAP
overexpression. Vinculin was used as loading control. Drug abbreviations as in Figure 1.
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in EGFR-resistant patients without other known mechanisms of
resistance.
Discussion
In our work, we aimed at evaluating the role of YAP in
EGFR-addicted lung cancer cells rendered resistant to first- or
second-generation EGFR TKIs. The Hippo pathway effector YAP
protein has long been recognized as a critical regulator of organ size
and is known to be involved in tumor initiation, progression, and
metastasis [14,17]. More recently, some works identified a role for
YAP in mediating resistance to targeted therapies [12]. Indeed, Shao
and colleagues showed that in a KRAS-driven murine lung cancer
model, acquired resistance to KRAS inhibition was due to YAP
activation, as both KRAS and YAP converge on the FOS transcription
factor and activate EMT [26]. In another work, Lin and collaborators
demonstrated that YAP acts as a parallel survival input to sustain
resistance to B-RAF and MEK inhibitors and that dual YAP/MEK
inhibition is synthetically lethal [22]. The authors found that both
YAP and MAPK control the expression of the antiapoptotic proteinBCL-xL and that the simultaneous inhibition of both pathways is
required to reduce BCL-xL expression to a level sufficient to restore
an apoptotic response. Another contribution to understanding the
role of YAP in mediating resistance came from the work of Kim et al.,
who found that resistance to BRAF inhibitors in melanoma cells was
due to actin remodeling-induced YAP activation [27]. In fact,
inhibition of actin polymerization and actomyosin tension suppressed
both YAP activation and resistance to BRAF inhibitors.
A role for YAP in mediating resistance to EGFR inhibition has also
been described [28,29]. In line with these evidences, we observed
increased YAP activation in all the generated EGFRTKI–resistant cells,
testified by decreased phosphorylation on the inhibitory serine 127,
enhanced nuclear localization, and augmented expression of its major
target CTGF. Interestingly, we detected YAP activation not only in cells
resistant to various EGFR TKIs but also in cells resistant to inhibitors
directed against other tyrosine kinases such as MET and ROS1. This
suggests that YAP activation may represent a more general mechanism
to sustain resistance to drugs targeting different tyrosine kinase
receptors. Hsu et al. recently reported a role for YAP in mediating
resistance to erlotinib in lung cancer cells [29]: they observed increased
Figure 4. Pharmacological or genetic blockage of AXL impinges on
HCC4006 cell viability. (A) HCC4006 resistant cells were maintained
in the presence of EGFR TKIs and co-treated with the AXL specific
inhibitor TP-0903 for 72 hours, and their viability was assessed. The
chart shows thatAXL inhibition throughTP-0903 reducedcell viability
in a dose-dependent manner. The error bars represent the SD.
**P b .01; ***P b .001. (B) HCC4006 cells were treated for 2 hours
with TP-0903, and the activation of AXL and of its main downstream
signal transducers AKT andMAPKwas evaluated byWB. As shown,
the phosphorylation of AXL (pAXL), AKT (pAKT), andMAPK (pMAPK)
was markedly reduced upon TP-0903 treatment. Actin was used as
loading control. (C) HCC4006 resistant cells (maintained in the
presence of EGFR TKIs) were transduced with two different AXL
shRNAsorwith a control shRNA (shC). Viabilitywasmeasured 6days
after seeding. Thechart shows thatAXL silencing strongly decreased
cell viability. The error bars represent the SD. ***P b .001. Drug
abbreviations as in Figure 1.
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resistant versus parental cells and YAP-mediated protection to erlotinib
treatment in parental cells. It has however to be noted that the reported
IC50 (2.48 μM) and the used doses of TKIs were dramatically higherthan those reported by others and ourselves ([8,30,31] and Table 1, in
the range of low nM). These authors also reported that H1975
erlotinib–resistant cells bearing the second site mutation T790M
became more sensitive to erlotinib upon YAP overexpression; the gain
in erlotinib efficacy, however, was very poor, and the mechanism
through which YAP rendered H1975 cells more sensitive to erlotinib
was not addressed.
To prove that YAP activation was not the consequence of resistance
onset but rather a critical element in sustaining resistance, we performed
experiments of genetic interference or exogenous protein expression in
resistant cells, which indeed demonstrated that lowering YAP activity
restored sensitivity to the different TKIs, while increasing it impaired
response to the drugs. As YAP is a transcriptional coactivator, we
reasoned that the observed effect could be due to the transcription of
critical effector(s). Among YAP targets, we focused on AXL, a tyrosine
kinase that has been identified as a mediator of YAP-dependent
oncogenic functions [25] and that has been shown to contribute to
resistance to targeted therapies [11]. In fact, Zhang et al. [11] showed
that AXL upregulation is sufficient to sustain erlotinib acquired
resistance in EGFR mutant NSCLC cellular models. In resistant cells,
we observed a YAP-dependent AXL increase concomitant with an
augmented expression of its ligand GAS6, resulting in autocrine
activation of this kinase. Pharmacologic inhibition and genetic
interference with AXL expression showed that AXL is critical in
mediating YAP-induced resistance to EGFR TKIs, thus representing an
actionable target to restore sensibility to targeted therapies. It is worth
noting that the described resistance is apparently not due to genetic
alterations but is rather sustained by an adaptive mechanism.
Interestingly, AXL silencing or pharmacological inhibition is more
effective than YAP silencing in reverting cancer cell resistance, suggesting
that othermechanisms— in addition to YAP activation—might concur
to AXL activation. It has been reported that AXL transcription can be
induced by MAPK-AP1 activation [32] and by MZF1 transcriptional
activity [33]. In this frame, the possible activation ofMAPK or ofMZF1
by other cellular stimuli might justify the primary role of AXL in
mediating resistance to EGFR TKIs we reported here.
Finally, we demonstrated that the activation of the YAP/AXL axis is
present in selected lung cancer patients who become resistant to EGFR
inhibitors. It is known that in about 50% of the cases, resistance to
EGFRTKIs is due to the appearance of resistancemutations, such as the
T790M. Accordingly, in seven lung cancer patients examined, we
found that this mutation was present in three biopsies obtained upon
resistance onset but not in the corresponding biopsies at diagnosis. In
one of the patients that did not show already described genetic
alterations supporting resistance, such as new EGFRmutations or ALK/
ROS1 translocations orMET amplification, we observed YAP activation
and AXL overexpression, recapitulating what was found in the in vitro
generated resistant cells. It is worthwhile to note that the activation of
the YAP-AXL pathway in one out of five patients negative for the
presence of the T790M mutation might represent a relatively high
percentage, in line with other mechanisms of resistance already
described, such as HER2 amplification [6]. Due to the relatively low
number of samples analyzed, however, other studies are needed to verify
the prevalence of YAP-AXL activation to understand the translation
potential of anti-AXL treatments into the clinic.
At present, drugs that specifically inhibit YAP activity are not
available. In fact, verteporfin, which was originally described as a
specific inhibitor of YAP-TEAD interaction, has been recently shown
to exert its activity through selective induction of proteotoxicity rather
Figure 5. YAP-AXL pathway becomes active upon erlotinib resistance onset in a lung cancer patient. Immunohistochemical evaluation
(immunoperoxidase) of CTGF, AXL, and pYAP expression in matched samples from a lung adenocarcinoma patient, at diagnosis (pleural
biopsy, histological grade G2; left part), and at the time of progression (liver biopsy, histological grade G3) under TKI inhibitors treatment;
original magnification for all figures, 200×.
Neoplasia Vol. 19, No. 12, 2017 YAP-induced AXL activation drives resistance to EGFR TKIs Ghiso et al. 1019than through YAP inhibition [34]. However, since, as discussed above,
AXL blockage is very effective in bypassing resistance, AXLmay represent
a more promising actionable target for patients' treatment. A clinical trial
testing the effect of cabozantinib (a multikinase inhibitor targeting also
AXL) is now recruiting selected patients (NCT01639508), and the first
clinical trial of the AXL selective inhibitor TP-0903 is expected to start
soon (NCT02729298).Conclusions
In conclusion, we identified YAP-driven AXL overexpression as a
mechanism of resistance to EGFR TKIs in lung cancer cells. Our dataadd a new mechanism of resistance to EGFR TKIs and could help
clinician to select the appropriate therapeutic strategy to overcome
resistance to targeted treatments in cancer patients.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.neo.2017.10.003.
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